The research collaboration will leverage Exscientia’s precision medicine platform to identify novel anticancer small molecule compounds. Promising candidates will be developed and potentially advanced into clinical trials at MD Anderson. Exscientia uses deep learning multiomics to test drug candidates in patient tissue models.
“We are driven to develop the next generation of oncology treatments that can offer meaningful benefits and improve the lives of our patients,” said Philip Jones, PhD, vice president of therapeutics discovery and head of the Institute for Applied Cancer Science at MD Anderson, in a Nov. 14 news release from the cancer center. “Our ultimate goal is to decrease the time we spend in drug development and accelerate novel targeted therapies into the clinic.”
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
